thoughts on these estimates, before EPS results? NASDAQ:ALHC, NASDAQ:PAVM, NASDAQ:AYTU, NYSE:IKT

ALIGNMENT HEALTHCARE (NASDAQ:ALHC) EARNINGS INFORMATION (NASDAQ:ALHC)

Alignment Healthcare last released its quarterly earnings results on May 16th, 2021. The reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.16. Alignment Healthcare has generated $0.00 earnings per share over the last year. Alignment Healthcare has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS ALIGNMENT HEALTHCARE A BUY RIGHT NOW? (NASDAQ:ALHC)

7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Alignment Healthcare in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Alignment Healthcare stock.
Alignment Healthcare

PAVMED (NASDAQ:PAVM) EARNINGS INFORMATION (NASDAQ:PAVM)

PAVmed last announced its earnings data on May 16th, 2021. The reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. PAVmed has generated $0.00 earnings per share over the last year. PAVmed has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 17th, 2021 based off prior year’s report dates.

IS PAVMED A BUY RIGHT NOW? (NASDAQ:PAVM)

4 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for PAVmed in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” PAVmed stock.
PAVmed

AYTU BIOPHARMA (NASDAQ:AYTU) EARNINGS INFORMATION (NASDAQ:AYTU)

Aytu Biopharma last released its quarterly earnings results on May 16th, 2021. The reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by $1.05. Aytu Biopharma has generated $0.00 earnings per share over the last year. Aytu Biopharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS AYTU BIOPHARMA A BUY RIGHT NOW? (NASDAQ:AYTU)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Aytu Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Aytu Biopharma stock.
Aytu Biopharma

INHIBIKASE THERAPEUTICS (NYSE:IKT) EARNINGS INFORMATION (NYSE:IKT)

Inhibikase Therapeutics last released its earnings data on April 1st, 2021. The reported ($0.15) EPS for the quarter. The business had revenue of $0.17 million for the quarter. Inhibikase Therapeutics has generated $0.00 earnings per share over the last year. Inhibikase Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS INHIBIKASE THERAPEUTICS A BUY RIGHT NOW? (NYSE:IKT)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Inhibikase Therapeutics stock.
Inhibikase Therapeutics